Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

By W. Liang, W. Guan, Ruchong Chen, Wei Wang, Jianfu Li, Ke Xu, Caichen Li, Qing Ai, Weixiang Lu, Hengrui Liang and 2 more. The Lancet Oncology, 2020

3,907 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/2065f7ed8e23bdca6bfdf00bfb6e88cbf29f3be5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. L. Garcia

Citations in the corpus

• Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis (2020, methodology): “those with malignancies, lung cancer patients seems to be more susceptible, and they must follow guidance on restricting any contact with possible infected zones or individuals for their safety (14).”
• Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis (2020, background): “Our review included 19 studies that were published between January 1, 2020, and February 21, 2020, most of them from China (18) and one from Australia (Table 1), including a total of 2874 patients, ranging from a case series of 9 [40] to a cross-sectional study of 1590 [41].”
• Knowledge, Perceptions, and Attitude of Egyptians Towards the Novel Coronavirus Disease (COVID-19) (2020, background): “The highly contagious virus, which caused the disease called coronavirus disease (COVID- 19) , spread outside China and has since become a global public health emergency [1] .”
• Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence (2020, neutral): “Therefore, it is particularly important to enhance self-resistance.”
• Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic (2020, background): “The few cases presented again appeared to be associated with the known risk factors for severe disease in the general population, rather than to factors related to cancer or its management (8).”
• Virology, Epidemiology, Pathogenesis, and Control of COVID-19 (2020, background): “cardiovascular diseases, and cancer may be more susceptible to SARS-CoV-2 [38,39].”
• A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group (2020, background): “Patients with cancer are more susceptible to infection than individuals without cancer, because malignancy and anticancer therapy result in an immunosuppressive state [7].”
• Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak (2020, background): “In addition, as age is one of the major predictors of severity of respiratory diseases like COVID-19 (4), we excluded from our analysis 117 younger COVID-19 patients without cancer so that median ages of patients with cancer (median = 64.”
• Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System (2020, background): “(8) Early case series from China and Italy have suggested that patients with malignancy are more susceptible to severe infection and mortality from COVID-19(9-12), a phenomenon that has been noted in other pandemics.”
• Predictors of COVID-19 severity: A literature review (2020, background): “A nationwide analysis in China showed that patients with various types of cancer, particularly hematological and pulmonary malignancies, have a higher probability of developing severe COVID-19 complications compared with patients without cancer.(35) This trend has been reported by others as well.”
• Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020, neutral): “Overall 525 363 (69) 161 (31) 24 (5) 21 (4) 16 (3) 37 (7) Age, y 0–9 3 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10–19 26 23 (88) 3 (12) 0 (0) 0 (0) 0 (0) 0 (0) 20–29 116 93 (80) 23 (20) 2 (2) 1 (1) 0 (0) 2 (2) 30–39 108 87 (81) 20 (19) 4 (4) 2 (2) 1 (1) 4 (4) 40–49 95 64 (67) 31 (33) 4 (4) 3 (3) 2 (2) ”